Vataseren 20mg PV Pharma medicine treats stable angina symptoms (2 blisters x 30 tablets)

Dosage form Box of 2 blisters x 30 tablets
Specifications Trimetazidine

Ingredient

Composition information	Content
Trimetazidine	20mg

Uses

indications

Vataseren is indicated in the following cases:

Trimetazidin is appointed to adults in additional therapies to support existing treatments to treat symptoms in patients with stable angina unproving or unposited patients with mainstream treatments.

Code ATC: C01EB15

Mechanism of action:

Trimetazidin inhibits the oxidation of fatty acids by inhibiting 3-ketoacyl-coa thiolase enzymes in the long-chain of ischemic cells, energy obtained during glucose oxidation needs to be less oxygen than the oxidation beta. Promoting glucose oxidation will help optimize cell energy processes, thus maintaining appropriate energy metabolism during anemia.

Pharmacological effects:

In patients with local myocardial ischemia, trimetazidin acts as a metabolic substance, which helps conserve high intracellular energy levels in myocardial cell. Trimetazidin has an anti -myocardial effect but does not affect hemodynamics.

Dynamic pharmacokinetics

absorption: Trimetazidin when taken is absorbed very quickly and reaches the peak concentration in plasma 2 hours after drinking. The maximum concentration of the drug in plasma, after taking a single dose of trimetazidin 20 mg, reaching about 55 nanogam/ml. The equilibrium of the drug in the blood is reached from 24 - 36 hours after repeating a dose and is very stable during treatment.

Distribution: Trimetazidine's distribution volume is 4.8 liters/kg, showing the good diffusion level of the drug to the tissues. The ratio of drug links to low plasma proteins, the measured value in vitro is 16%.

Metabolism and elimination: half -life of trimetazidine is 6 hours. The drug is excreted mainly in urine in the form of unprovered.

Before taking Vataseren 20mg PV Pharma medicine treats stable angina symptoms (2 blisters x 30 tablets)

How to use

oral tablets.

Dosage

Take 1 capsule/time x 3 times/day, drink with meals.

Need to re -evaluate the benefits of treatment after 3 months of treatment. If the drug does not respond, then stop using it.

on special subjects:

Patients with renal failure:

Patients with average renal impairment (CL from 30 - 60 ml/minute): It is recommended to be recommended for 1 tablet/time, 2 times/day, drinking morning and evening, using meals.

Elderly:

In the elderly, trimetazidine levels may increase due to impaired renal function. If patients with average renal insufficiency (CL from 30 - 60 ml/minute): should be recommended for 1 tablet/time, 2 times/day, drinking morning and evening, serving with meals. When adjusting the dose in the elderly, it is necessary to do it carefully.

Children:

Safety and effectiveness of trimetazidin for patients under 18 years of age has not been evaluated. There is currently no data on this patient object.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Symptoms of overdose:

The information reported when using overdose is very small.

Management:

Need to treat symptoms and support if necessary.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? Do not use double to compensate for the dose has forgotten to drink.

Side Effects

When using the drug, there are common unwanted effects (ADR) such as:

Common, ADR> 1/100:

Neurological: Dizziness, headache.

Disorders on the cardiovascular system: Brushing chest drums, extra mind, thrilling, fast heartbeat. Aortic hypotension, posture hypotension can lead to discomfort, dizziness or falling, especially in patients being treated with anti -hypertension drugs, flushing.

Symptoms Parkinson (Run, slow and difficult exercise, muscle tone), unstable gait, vacuum syndrome, other relevant movement disorders, often recovered after medication. Seeds, thrombocytopenia, platelet hemorrhage. Hepatitis.

Instructions on how to handle ADR:

Notify the physician with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Vataseren drugs contraindicated in the following cases:

Hypersensitivity to trimetazidin or any ingredients of the drug.

Be cautious when using

Please see more information about the drug in the instruction sheet of the use of the drug attached.

Trimetazidin is not a medication for angina, nor is not prescribed the first choice for unstable angina or myocardial infarction or before hospitalization or the first days when hospitalized.

In the event of an angina occurrence when using the drug, it is necessary to re -evaluate coronary artery disease and consider the response to treatment (drug treatment and may have blood vessels).

Trimetazidine can cause or worsen the symptoms of Parkinson's disease (slow and difficult and difficult movement, and increase muscle tone). Therefore, patients, especially elderly patients, should be checked and monitored regularly. In suspicious cases, patients need to be taken to neurologists for appropriate examination.

When encountering movement disorders such as Parkinson's symptoms, feet syndrome, unstable gait, it is necessary to immediately stop using trimetazidin.

These cases are rarely occurring and often recover after stopping the drug. Most patients recover after stopping the drug for about 4 months. If Parkinson's symptoms continue to happen for more than 4 months after stopping the drug, consulting neurologists.

When using the drug may experience the self, unstable gait or hypotension, especially in patients who are taking drugs to treat hypertension (see more unwanted effects).

Be careful when prescribing Trimetazidin for patients with high sensitivity levels such as patients with average renal impairment, patients over 75 years old (see more dose and usage).

Trimetazidin should not be recommended for pregnant or lactating women (see the part of pregnancy and nursing mothers).

In some cases when using the drug, patients may feel dizzy, headache, drowsiness, so limit driving or using machines if there are these abnormal signs.

The effect of the drug on driving and operating machinery

In clinical trial studies shows that trimetazidin does not affect hemodynamics, but the reported after circulation can cause symptoms such as dizziness, drowsiness, so it should be limited to driving or using machines if there are these abnormal signs.

Use drugs for women during pregnancy and lactation

Pregnancy

Animal research results have not been confirmed for sure whether or not the teratical effect of trimetazidin. However, there is not enough clinical evidence to eliminate the risk of fetal defects. Therefore, to ensure safety, it is best to avoid using trimetazidin during pregnancy.

Breastfeeding period

There is no evidence of the presence of trimetazidin in breast milk, so the best option is not to breastfeed during trimetazidine treatment.

Interactive drug

There has been no interaction with any drug. Trimetazidin is not an induction drug nor is a drug inhibiting the liver metabolic enzyme in the liver and thus is more likely to trimetazidin does not interact with many metabolic drugs in the liver.

Anyway, you still need to be careful to monitor when coordinated with another drug.

Storage

In a dry place, temperatures below 30 ° C, avoid light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.